Sutro Biopharma (STRO) Share-based Compensation (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Share-based Compensation data on file, last reported at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 72.02% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $19.4 million (up 2.03% YoY), and the FY2025 full-year result was $14.0 million, down 43.26% from the prior year.
• Share-based Compensation eased to $1.7 million in Q4 2025, from $9.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $39.6 million in Q3 2022 to a low of $374000.0 in Q1 2024.
• A 5-year average of $10.5 million and a median of $6.4 million in 2021 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 98.22% in 2023 and surged 1477.54% in 2025, its largest moves.
• Tracing STRO's Share-based Compensation over 5 years: stood at $6.9 million in 2021, then jumped by 275.21% to $25.8 million in 2022, then sank by 75.92% to $6.2 million in 2023, then slipped by 4.95% to $5.9 million in 2024, then slumped by 72.02% to $1.7 million in 2025.
• Business Quant data shows STRO's Share-based Compensation at $1.7 million in Q4 2025, $9.4 million in Q3 2025, and $5.3 million in Q2 2025.